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Abstract 
An International Symposium on Integrative Molecular Cancer Epidemiology took place in Lyon, France, on 3–5 July 2008. The 
Symposium focused on aetiological and mechanistic aspects of molecular and genetic cancer epidemiology research and was divided 
into the following three sections: 
(1) Molecular epidemiology—application of novel molecular markers to cancer epidemiology. 
(2) Genomic epidemiology in the era of whole genome scan. 
(3) Integrative molecular epidemiology: visions for the future. 
Participants included epidemiologists, geneticists, biochemical and molecular biologists, pharmacologists, pathologists and all 
researchers interested in this field. The Symposium provided a complete and clear overview of the present and future programmes in 
molecular cancer epidemiology. It also served to encourage international scientific collaboration between investigators working in this 
specific research field, and to stimulate transdisciplinary research with experts of other research areas. Highlights of each of the scientific 
presentations are summarized below. 
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Introduction 
Over the last two decades molecular epidemiology has 
developed as an independent discipline, which aims to 
overcome some limitations of traditional epidemiology and to 
offer a framework for applying novel molecular techniques to 
population and clinical studies. Furthermore, the development of 
the HAPMAP project and the advent of new technologies for 
genotyping hundreds of thousands of variants for a limited cost 
have led to a new generation of studies aimed at identifying 
genes associated with several diseases.  
Cancer research has represented a good target area for the 
theoretical development and the application of molecular 
epidemiology due to the long duration of disease development, 
the heterogeneity of the relevant phenotypes, and the 
complexity of carcinogenic pathways. 
An international symposium on Integrative Molecular Cancer 
Epidemiology took place in Lyon, France, on 3–5 July 2008, 
immediately before the 20th meeting of the European 
Association of Cancer Research. It provided an opportunity for 
investigators to present their work and to review the most 
promising areas of future development of molecular cancer 
epidemiology. The Symposium focused on aetiological and 
mechanistic aspects of molecular and genetic cancer 
epidemiology research, which have been addressed through the 
interplay of epidemiologists, clinicians and molecular biologists. 
Participants therefore included epidemiologists, geneticists, 
biochemical and molecular biologists, pharmacologists, 
pathologists and all the researchers interested in this field. 
After the opening speech by Paolo Boffetta (IARC, Lyon), the 
first invited speaker, Frederica Perera, from Columbia 
University, New York, provided an overview of the main findings 
in molecular epidemiology from its first applications in cancer 
research in the early 1980s. A first example of a successful 
application was the measurement of chemical-specific DNA 
adducts formed by the interface between environmental 
exposures, like polycyclic aromatic hydrocarbons and DNA, a 
toxicological target. By measuring DNA adducts, researchers 
could identify individuals who are likely to be at increased risk 
for developing cancer after exposure to specific carcinogens. 
Further important findings included the association of 
chromosomal aberrations with cancer risk, and that individuals 
with specific genetic polymorphisms or nutritional deficits could 
be more susceptible to cancer. On the other hand, molecular 
epidemiology has failed to measure the full spectrum of pre-
clinical alterations resulting from carcinogen exposure thus 
precluding clear gains in terms of cancer prevention. In order to 
address these gaps new epigenetic and ‘omic’ biomarkers have 
recently became available, but they need to be systematically 
validated using principles and criteria established over the past 
few decades in the epidemiology and molecular epidemiology of 
cancer. These new biomarkers can be used in combination with 
the earlier validated biomarkers of exposure, risk and 
susceptibility to identify ‘at risk’ individuals, increase our 
understanding of mechanistic carcinogenic pathways, and 
mount more effective intervention to prevent cancer occurrence. 
In order to allow in-depth discussions of the different tasks, the 
Symposium was divided into the following three sections:  
(1) Molecular epidemiology—application of novel molecular 
markers to cancer epidemiology.  
(2) Genomic epidemiology in the era of whole genome scan.  
(3) Integrative molecular epidemiology: visions for the future. 
 
Molecular epidemiology—application of 
novel molecular markers to cancer 
epidemiology 
Michael Pawlita (German Cancer Research Centre, DKFZ, 
Heidelberg) discussed newly developed high-throughput 
multiplex technologies for the simultaneous, quantitative 
detection of antibodies, up to 100 different viral or bacterial 
proteins, or the genomes of broad varieties of viruses and 
bacteria, providing some examples of their application to large 
cross-sectional, case-control and infection prevalence studies. 
An overview on the application of epigenetics to cancer 
epidemiology was provided by Zdenko Herceg (IARC, Lyon), 
who highlighted that epigenetics play key roles in virtually all 
stages of cancer development and progression. The term 
‘epigenetics’ refers to all heritable changes in gene expression 
and associated phenotypic traits that are not coded in the DNA 
sequence itself. Several critical processes found in cancer cells, 
such as silencing of tumour suppressor genes, activation of 
oncogenes, aberrant cell cycle, and defects in DNA repair, can 
be a consequence of not only genetic but also epigenetic 
changes, which could be induced by environmental, dietary and 
lifestyle factors. Epigenetic inheritance includes DNA 
methylation, histone modifications, and micro-RNAs. Epigenetic 
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profiling using both genome-wide and candidate-gene 
approaches in different tumour types will help in elucidating the 
mechanism underlying tumourigenesis. 
The next invited speaker, Anne-Lise Borresen-Dale (Institute for 
Cancer Research, Oslo) presented applications of expression 
micro-arrays on breast cancer epidemiology. By expression 
profiling on healthy and tumour breast tissue, they identified a 
gene signature of 82% accuracy, 87% sensitivity and 76% 
specificity for breast cancer diagnosis. They also found that the 
previously identified gene set efficiently discriminates breast 
cancer and non-breast cancer samples from a further study 
population, providing evidence for a gene expression signature 
as a potential additional tool in breast cancer diagnostic work-
up. 
Marco Pierotti (National Cancer Institute, Milan) focused his talk 
on gene expression analysis, by explaining how they tried to 
identify expression profiles potentially predictive of response to 
treatment, using an accessible source, such as blood. He used 
as an example the application of expression analysis to the 
study of toxicity from ionizing radiation therapy in cancer, with 
the hypothesis that some cases of toxicity could be associated 
with abnormal transcriptional response to radiation. 
The last two presentations within the first session focused on 
proteomics. The first speaker, Samir Hanash (Fred Hutchinson 
Cancer Research Center, Seattle), discussed the current status 
of the field and emerging findings, underlying that current 
proteomic strategies allow quantitative profiling of cells, tissues 
and biological fluids, and identify proteins changes resulting 
from altered levels, post-translational modifications and amino 
acid substitutions. A major application of proteomics is 
assessment of health-related changes in the plasma proteome. 
Roel Vermeulen (University of Utrecht) discussed the possibility 
of applying proteomics to epidemiological studies. The function 
of a cell can be described by the proteins that are present in the 
cell and the abundance of these proteins. Proteomics has 
theoretical advantages over genomics and transcriptomics; 
however, it might not be ready, at this point, to be used in large-
scale (prospective) epidemiological research. This is due to 
major challenges that still need to be overcome both 
technologically (the ability to reliable detect a wide range of 
proteins) and epidemiologically (study design, sample 
collection, information on inter- and intra-individual variability).  
Two proffered papers were further presented within the first 
section of the Symposium: the first one by KB Ribeiro (IARC, 
Lyon) was on serological response to HPV and the risk of head 
and neck cancer, while the second one by Q Wei (Anderson 
Cancer Center, Houston) presented the results from a study on 
in vitro benzo[a]pyren diol epoxide-induced damage to DNA and 
chromosomes as independent risk markers for squamous cell 
carcinoma of the head and neck. 
 
Genomic epidemiology in the era of whole 
genome scan 
The second section was opened by Nazneen Rahman (The 
Institute of Cancer Research, Sutton, London) who presented 
her experience in breast cancer case-control mutation 
screening. She highlighted that there were three delineated 
components of the genetic architecture of breast cancer. The 
first ones are rare, high penetrance (>10-fold) autosomal 
dominant cancer predisposition genes such as BRCA1 and 
BRCA2; the second ones are common, low penetrance (<1.5-
fold) susceptibility alleles that have emerged from genome-wide 
tag-SNP searches in breast cancer; and the third ones are rare, 
intermediate penetrance (2 to 4-fold) susceptibility alleles 
discovered through large-scale, case-control resequencing 
analyses. They have identified four DNA repair genes, ATM, 
CHEK2, BRIP1 and PALB2, which seem to play a role in breast 
cancer and exemplified this final class. 
An application of Genome Wide Association studies (GWAS) to 
lung cancer was presented by Paul Brennan (IARC, Lyon). 
They conducted a GWAS on 317,139 SNPs in 1989 lung cancer 
cases and 2625 controls from six central European countries. 
They identified a locus in chromosome region 15q25 that was 
strongly associated with lung cancer. This locus was replicated 
in five separate lung cancer studies comprising an additional 
2518 lung cancer cases and 4752 controls, and it was found to 
account for 14% of lung cancer cases. The association region 
contains several genes, including three that encode nicotinic 
acetylcholine receptor subunits (CHRNA5, CHRNA3 and 
CHRNB4). 
The developed statistical approaches for GWAS were 
discussed by David Balding from Imperial College, London. He 
highlighted the limitations of most approaches that were simple 
one-SNP-at-time analysis with adjustments for population 
structure and with cryptic kins removed. He presented 
alternative approaches that could improve the power of this 
technique, by analysing multiple SNPs simultaneously with 
more sophisticated adjustments for population structure and 
cryptic kinship. Gene–gene and gene–environment interactions 
have not yet been widely reported but could be incorporated in 
future studies. 
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Xavier Estivill (CIBERESP and Pompeu Fabra University, 
Barcelona) highlighted the important role of copy number 
variants (CNV) in complex diseases like cancer. Several CNV 
are present in each individual and may contain genes with roles 
in response to the environmental and adaptation. It is therefore 
likely that regions containing CNVs might have important roles 
in drug-response, susceptibility to infection, inflammation and 
cancer. The mechanisms by which CNVs could have functional 
consequences include a direct gene dosage effect of the gene 
or genes embedded in the CNV, or a positional effect on genes 
proximal or distal to the CNV. By comparing samples from 12 
population groups, they identified over 200 genomic regions that 
varied in the genomic structure between groups. Most of these 
regions coincided with already known CNVs and segmental 
duplications and contained genes with a role in immune 
response, adaptation to environment, and metabolic pathways. 
Rodolfo Saracci (National Research Council, Pisa) discussed 
the applicability of molecular cancer epidemiology to public 
health. Until now, results from molecular cancer epidemiology 
studies have not been translated into significant prevention 
advances at the population level. However there is often a time-
lag between novel research approaches and practical 
applications. Cervical cancer is the most relevant example of 
the recent practical application of molecular epidemiology: the 
aetiological link with human papilloma viruses has been 
established by advanced molecular epidemiology techniques, 
and the detection of the virus in cervical cells has come into 
discussion as complement to the pap-test for screening 
purposes. An ‘integrative epidemiology’ approach, which 
combines the study of environmental exposures, susceptibility 
biomarkers and biomarkers for molecular sub-typing of cancers, 
may lead to a more refined stratification of risk by individual 
traits and by cancer type, paving the way to individualized 
prevention. 
Many interesting proffered papers and posters have been 
discussed within this session of the Symposium. Among them, 
two studies carried out within the European Prospective 
Investigation into Cancer and Nutrition cohort: the first one by A 
van Winden (The Netherlands Cancer Institute, Amsterdam) 
searched for early breast cancer biomarkers by serum protein 
profiling; the second one by M Jenab (IARC, Lyon) studied the 
circulating vitamin D concentration, Vitamin D Receptor 
polymorphisms and the risk of colorectal cancer. Other 
interesting papers include: one by HB Shen (Cancer Center of 
Nanjing Medical University) on genetic variants in fibroblast 
growth factor receptor 2 in breast cancer susceptibility in 
Chinese women; one by T. Hayashi (Radiation Effects 
Research Foundation, Hiroshima) on the effects of IL-10 and IL-
6 gene polymorphisms and atomic-bomb radiation exposure on 
gastric cancer risk; one by E De Feo (Catholic University, 
Rome) presenting a case-control study on the effect of p53 and 
p73 polymorphisms on gastric cancer risk and progression in an 
Italian population and the special lecture by L Beretta on viral 
hepatitis and liver cancer.  
 
Integrative molecular epidemiology: visions 
for the future 
The last session was opened by Nathaniel Rothman (National 
Cancer Institute, Bethesda), who discussed gene–environment 
interactions. He presented the results of a previously published 
study on the association between N-acetyl transferases 2 
(NAT2) and gluthatione S-transferases-M1 (GSTM1) 
polymorphisms with bladder cancer risk. They evaluated 
heterogeneity among risk estimates by ethnic groups and 
assessed gene–smoking interaction. They found a significant 
interaction between NAT2 and the number of cigarettes per day 
in bladder cancer risk by case-only analysis, while the risk 
estimate for GSTM1 was not modified by ethnicity nor by 
smoking intensity. 
Julia Ross (University of Minnesota Cancer Center, 
Minneapolis) presented a transdisciplinary study applied to 
epidemiology of childhood leukaemia. First, they investigated 
the potential role of environmental exposures (i.e. maternal folic 
acid, pesticides) in murine models through tracking disease 
outcome and gene methylation and expression in appropriate 
target cells in offspring. They identified 33 genes as differentially 
expressed between the offspring of mothers assigned to 
different dietary groups and selected five of these genes for 
validation by comparative RT-PCR. Second, they established a 
pregnancy cohort to investigate the functional relationship 
between specific exposures and their biomarkers in cord blood 
and neonatal blood spots in relation to relevant risk factors and 
genetic polymorphisms of interest. 
John Ioannidis (University Ioannina School of Medicine, 
Ioannina) discussed how to evaluate cumulative evidence in 
genomic epidemiology. With the advent of massive-testing high-
throughput platforms, there is an increasing amount and 
complexity of data; therefore, the concept of sufficient 
replication has evolved over time with more stringent criteria 
now required to claim that an association has a robust 
credibility. During a Venice meeting, criteria were proposed to 
appraise the evidence of genetic association; the criteria have 
three axes: amount of evidence, replication consistency and 
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protection from bias. Each of the three axes is rated from A to 
C. Associations that get an A in all three axes are considered to 
have ‘strong’ epidemiological credibility; those that get at least 
one B but no C are considered to have ‘moderate’ 
epidemiological credibility and those that get at least one C are 
graded as having ‘weak’ credibility. 
A transdisciplinary science approach for molecular 
epidemiology was discussed by Robert Hiatt (University of 
California, San Francisco). This approach is needed to integrate 
the study of the biological nature of cancer and its clinical 
applications with behavioural and social influences on cancer. 
Moreover, this may be a more effective way to apply the 
findings of molecular epidemiology for use in therapeutic, 
behavioural and public health interventions, by seeking to 
discover interactions between social, environmental, 
behavioural and biologic factors in cancer aetiology. 
Gilles Thomas (National Cancer Institute, Bethesda) discussed 
the impact of whole genome scans on cancer research, which is 
especially important for less common cancers (i.e. pancreas 
and kidney cancer) and for sub-types predisposition (i.e. in 
colorectal and breast cancer). GWAS are useful to identify the 
locus of interest, but then it is necessary to search for the 
specific variant in that region, which is associated with the 
disease. Although this search could be done through linkage 
disequilibrium analysis, this could be hard to do for most regions 
for which there is not a candidate gene. For the future, it is 
necessary to develop new statistical methods for multi-SNPs 
association, build networks that explain and summarize the 
  gene–environment interaction in different tumours, identify a 
reliable genetic risk model, which incorporates genotypes from 
multiple loci, and finally test a first-proposed simple model within 
international collaborative studies. 
The congress was closed with Martyn Smith’s presentation 
(University of California, Berkeley) on the future perspectives of 
molecular cancer epidemiology. In the future, we will probably 
witness the final development of the ‘omic’ technologies, such 
as transcriptomics, proteomics and metabolomics. Also, the 
epigenome has not been fully explored to date, but new micro-
arrays that measure hundreds of micro-RNAs or the CpG 
promoter methylation status of hundred of genes are now 
available. Finally, advances in nanotechnology should allow for 
multiplexed immuno-assay of protein adducts, cytokines and 
antibodies in very small quantities of human material. Since 
about 90% of cancer risk is explained by environmental factors 
and 10% by genetics, probably in the not-too-distant future 
molecular cancer epidemiology will be revolutionized by the 
emerging field of exposure biology. 
 
Conclusions 
The Symposium was very useful in providing a complete and 
clear overview of the present and future of molecular cancer 
epidemiology because of very interesting presentations by all 
the speakers. It was also useful both to encourage international 
scientific collaboration between investigators working in this 
specific research field, and to stimulate transdisciplinary 
research with experts of other research areas. 
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